Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Imunon (IMNN – Research Report) and keeping the price target at $14.00.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Emily Bodnar’s rating is based on the promising results from Imunon’s OVATION 2 study, which were highlighted at major conferences like ASCO and ESMO. The study demonstrated that IMNN-001, when combined with chemotherapy, significantly improved overall survival and progression-free survival in patients with advanced ovarian cancer compared to standard care. The data showed a median increase in overall survival of 13 months and a 3-month increase in progression-free survival, alongside a favorable safety profile without severe adverse events.
Furthermore, the treatment showed enhanced efficacy in patients with specific genetic markers, such as BRCA mutations, and demonstrated superior surgical outcomes with a higher rate of complete tumor removal. The recent financial moves by Imunon, including securing $3.25 million through a private placement, provide the necessary capital to advance their Phase 3 OVATION 3 study. These factors collectively support the Buy rating, as they indicate strong potential for IMNN-001’s continued success and market impact.
According to TipRanks, Bodnar is an analyst with an average return of -8.2% and a 27.35% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Agenus, and Imunon.